跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
黃 怡翔
教授
臨床醫學研究所
電話
(02) 28712121 ext.3055
電子郵件
yhhuang
vghtpe.gov
tw
h-index
h10-index
h5-index
14710
引文
54
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
9801
引文
38
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
4134
引文
29
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1997 …
2024
每年研究成果
概覽
指紋
網路
研究成果
(441)
類似的個人檔案
(6)
指紋
查看啟用 Yi-Hsiang Huang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Advanced Hepatocellular Carcinoma
8%
Albumin-bilirubin Grade
13%
Alpha-fetoprotein
10%
Antiretroviral Therapy
5%
Ascites
5%
Barcelona Clinic Liver Cancer
8%
Chronic Hepatitis B
8%
Chronic Hepatitis B Patients
5%
Chronic Hepatitis C
14%
Cirrhosis
13%
Cirrhotic Patients
7%
Confidence Interval
13%
Cox Proportional Hazards Model
5%
Direct-acting Antivirals
9%
Hazard Ratio
13%
Hepatitis B
5%
Hepatitis B e Antigen (HBeAg)
5%
Hepatitis B Surface Antigen (HBsAg)
9%
Hepatitis B Virus
11%
Hepatitis C
13%
Hepatitis C Virus
13%
Hepatitis D Virus
5%
Hepatocellular Carcinoma
94%
Hepatocellular Carcinoma Patients
24%
Immune Checkpoint Inhibitors
7%
Liver
5%
Liver Cirrhosis
7%
Liver Reserve Function
6%
Locoregional Therapy
6%
MELD Score
7%
Microvascular Invasion
5%
Milan Criteria
5%
Multivariate Analysis
7%
Overall Survival
13%
Performance Status
6%
Portal Hypertension
5%
Prognostic Factors
9%
Prognostic Impact
5%
Prognostic Model
5%
Propensity Score Analysis
7%
Radiofrequency Ablation
13%
Resection
6%
Risk Factors
7%
Surgical Resection
11%
Sustained Virological Response
8%
Taiwan
24%
Transarterial Chemoembolization
18%
Tumor Recurrence
5%
Tumor Size
5%
Unresectable Hepatocellular Carcinoma
7%
Medicine and Dentistry
Antiviral Therapy
6%
Antivirus Agent
7%
Bilirubin
13%
Cancer Staging
8%
Chronic Hepatitis B
8%
Chronic Hepatitis C
11%
Fetoprotein
5%
Fibrosis
5%
Hazard Ratio
10%
Hepatitis B
7%
Hepatitis B Virus
13%
Hepatitis C
6%
Hepatitis C Virus
8%
Hepatocellular Carcinoma
100%
Immune Checkpoint Inhibitor
5%
Immunotherapy
5%
Liver Cancer
11%
Liver Cirrhosis
17%
Malignant Neoplasm
5%
Milan Criteria
6%
Model for End-Stage Liver Disease
5%
Multivariate Analysis
5%
Neoplasm
17%
Overall Survival
13%
Platelet
8%
Proportional Hazards Model
6%
Radiofrequency Ablation
11%
Recurrent Disease
5%
Surgery
15%
Transcatheter Arterial Chemoembolization
19%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
5%
Antivirus Agent
13%
Bilirubin
12%
Cancer Staging
5%
Chronic Hepatitis B
11%
Chronic Hepatitis C
12%
Disease
7%
End Stage Liver Disease
6%
Fetoprotein
5%
Fibrosis
6%
Hepatitis B
8%
Hepatitis B Antigen
6%
Hepatitis B Virus
19%
Hepatitis B(e) Antigen
6%
Hepatitis C
8%
Hepatitis C Virus
9%
Immune Checkpoint Inhibitor
7%
Immunotherapy
6%
Infection
7%
Liver Cell Carcinoma
85%
Liver Cirrhosis
15%
Liver Fibrosis
6%
Liver Injury
5%
Malignant Neoplasm
6%
Mouse
8%
Neoplasm
16%
Nonalcoholic Fatty Liver
5%
Overall Survival
15%
Progression Free Survival
5%
Recurrent Disease
7%
Sofosbuvir
5%
Sorafenib
5%
Tumor Recurrence
5%
